CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 4, 2006
Result type: Reports
Project Number: SR0088-000
Product Line: Reimbursement Review

Generic Name: Telbivudine

Brand Name: Sebivo

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Hepatitis B (chronic)

Indications: Hepatitis B (chronic)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 26, 2007

Recommendation Type: Do not list